Eric ONeill
Overview
Explore the profile of Eric ONeill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chatzifrangkeskou M, Stanly T, Koennig D, Campos-Soares L, Eyres M, Hasson A, et al.
Sci Adv
. 2025 Feb;
11(7):eadr5683.
PMID: 39951537
The mechanical environment is sensed through cell-matrix contacts with the cytoskeleton, but how signals transit the nuclear envelope to affect cell fate decisions remains unknown. Nuclear actin coordinates chromatin motility...
2.
Russell S, Demetriou C, Valenzano G, Evans A, Go S, Stanly T, et al.
Gut
. 2025 Jan;
PMID: 39788719
Background: The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical studies have implicated macrophage-mediated immune tolerance. Hence, pathways that regulate macrophage phenotype are of strategic interest,...
3.
Ye Y, Xie W, Wang X, Tan S, Yang L, Ma Z, et al.
Cell Mol Life Sci
. 2025 Jan;
82(1):38.
PMID: 39762370
The mechanism by which DNA-damage affects self-renewal and pluripotency remains unclear. DNA damage and repair mechanisms have been largely elucidated in mutated cancer cells or simple eukaryotes, making valid interpretations...
4.
Valenzano G, Russell S, Go S, ONeill E, Jones K
Curr Protoc
. 2024 Oct;
4(10):e70032.
PMID: 39432378
Mouse models remain at the forefront of immuno-oncology research, providing invaluable insights into the complex interactions between the immune system and developing tumors. While several flow cytometry panels have been...
5.
Mora-Boza A, Mulero-Russe A, Di Caprio N, Burdick J, ONeill E, Singh A, et al.
Nat Protoc
. 2024 Sep;
20(1):272-292.
PMID: 39266725
Perfusable hydrogels have garnered substantial attention in recent years for the fabrication of microphysiological systems. However, current methodologies to fabricate microchannels in hydrogel platforms involve sophisticated equipment and techniques, which...
6.
Xu H, Russell S, Steiner K, ONeill E, Jones K
Cancer Immunol Immunother
. 2024 Aug;
73(10):204.
PMID: 39105848
The intricate interplay between immune and stromal cells within the tumour microenvironment (TME) significantly influences tumour progression. Myeloid cells, including tumour-associated macrophages (TAMs), neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs),...
7.
Mukherjee S, Qi C, Shaw R, Jones C, Bridgewater J, Radhakrishna G, et al.
Eur J Cancer
. 2024 Jul;
209():114236.
PMID: 39059185
Background: The multi-centre two-stage SCALOP-2 trial (ISRCTN50083238) assessed whether dose escalation of consolidative chemoradiotherapy (CRT) or concurrent sensitization using the protease inhibitor nelfinavir improve outcomes in locally advanced pancreatic cancer...
8.
Hughes D, Evans A, Go S, Eyres M, Pan L, Mukherjee S, et al.
Sci Adv
. 2024 Jul;
10(27):eadm9071.
PMID: 38968363
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, a disease with dismal overall survival. Advances in treatment are hindered by a lack of preclinical models. Here,...
9.
Tesson M, Stevenson K, Karim S, Nixon C, Chalmers A, Sansom O, et al.
Dis Model Mech
. 2024 Feb;
17(3).
PMID: 38421046
The value of radiotherapy in the treatment of pancreatic cancer has been the subject of much debate but limited preclinical research. We hypothesise that the poor translation of radiation research...
10.
Miller P, Akama-Garren E, Owen R, Demetriou C, Carroll T, Slee E, et al.
Cell Death Differ
. 2023 Jun;
30(7):1619-1635.
PMID: 37270580
Oncogenic KRAS activation, inflammation and p53 mutation are key drivers of pancreatic cancer (PC) development. Here we report iASPP, an inhibitor of p53, as a paradoxical suppressor of inflammation and...